240 related articles for article (PubMed ID: 11377343)
1. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.
Chang SS; Reuter VE; Heston WD; Gaudin PB
Urology; 2001 Jun; 57(6):1179-83. PubMed ID: 11377343
[TBL] [Abstract][Full Text] [Related]
2. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
3. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
[TBL] [Abstract][Full Text] [Related]
4. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.
Chang SS; Reuter VE; Heston WD; Gaudin PB
Urology; 2001 Apr; 57(4):801-5. PubMed ID: 11306418
[TBL] [Abstract][Full Text] [Related]
5. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
7. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
Ross JS; Sheehan CE; Fisher HA; Kaufman RP; Kaur P; Gray K; Webb I; Gray GS; Mosher R; Kallakury BV
Clin Cancer Res; 2003 Dec; 9(17):6357-62. PubMed ID: 14695135
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Sweat SD; Pacelli A; Murphy GP; Bostwick DG
Urology; 1998 Oct; 52(4):637-40. PubMed ID: 9763084
[TBL] [Abstract][Full Text] [Related]
9. The clinical role of prostate-specific membrane antigen (PSMA).
Chang SS; Heston WD
Urol Oncol; 2002; 7(1):7-12. PubMed ID: 12474535
[TBL] [Abstract][Full Text] [Related]
10. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
[TBL] [Abstract][Full Text] [Related]
11. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
Ananias HJ; van den Heuvel MC; Helfrich W; de Jong IJ
Prostate; 2009 Jul; 69(10):1101-8. PubMed ID: 19343734
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Bostwick DG; Pacelli A; Blute M; Roche P; Murphy GP
Cancer; 1998 Jun; 82(11):2256-61. PubMed ID: 9610707
[TBL] [Abstract][Full Text] [Related]
13. The utility of monoclonal antibodies in the imaging of prostate cancer.
Yao D; Trabulsi EJ; Kostakoglu L; Vallabhajosula S; Joyce MA; Nanus DM; Milowsky M; Liu H; Goldsmith SJ
Semin Urol Oncol; 2002 Aug; 20(3):211-8. PubMed ID: 12215974
[TBL] [Abstract][Full Text] [Related]
14. Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.
Jia L; Jiang Y; Michael CW
Diagn Cytopathol; 2017 Nov; 45(11):998-1004. PubMed ID: 28888085
[TBL] [Abstract][Full Text] [Related]
15. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.
Murphy GP; Elgamal AA; Su SL; Bostwick DG; Holmes EH
Cancer; 1998 Dec; 83(11):2259-69. PubMed ID: 9840525
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.
Gong MC; Chang SS; Sadelain M; Bander NH; Heston WD
Cancer Metastasis Rev; 1999; 18(4):483-90. PubMed ID: 10855791
[TBL] [Abstract][Full Text] [Related]
18. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.
Wolf P; Freudenberg N; Bühler P; Alt K; Schultze-Seemann W; Wetterauer U; Elsässer-Beile U
Prostate; 2010 Apr; 70(5):562-9. PubMed ID: 19938014
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells.
Barren RJ; Holmes EH; Boynton AL; Misrock SL; Murphy GP
Prostate; 1997 Jan; 30(1):65-8. PubMed ID: 9018338
[TBL] [Abstract][Full Text] [Related]
20. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
